Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

/in

Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables direct discovery of functionally active molecules against difficult to drug targets expressed in their native intracellular environment Southampton, UK, 16th February 2022: Curve Therapeutics (Curve), a private biotechnology company pioneering a potentially […]

Read more

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

/in

Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners Unique Protein Splicing platform enables efficient delivery of large genes with adeno- associated vectors (AAV) Proceeds will be used to advance the lead program in Stargardt disease into the clinic and expand pipeline […]

Read more

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

/in

Promising non-clinical results support Phase 1 clinical study in recurrent GBM Commitment to ensuring I-123 PARPi is available to treat the unmet medical need of patients diagnosed with primary and recurrent GBM LONDON, UK, 10 February 2022 – Theragnostics, which is developing radiopharmaceuticals for imaging and treatment of cancer, today announces that its novel I-123 […]

Read more

Destiny Pharma: Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme

/in

Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme Phase 3 can use similar primary endpoint to the very successful Phase 2b clinical study New European report underpins clinical need and market opportunity of XF-73 Nasal Brighton, United Kingdom, 8 February 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Read more

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/in

Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early Significantly less aggressive critical care with maintained renal function in young adults New patent filed for efficacious treatment window Discussions with US and EU regulators to support market authorization initiated vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular […]

Read more